One size rarely fits all – this is especially true with Nanoparticle formulation.
Commercialisation of a technology generally simplifies the system to meet a vast array of needs but ultimately limits the functionality. As emerging discoveries push the boundaries of what is possible in RNA delivery and nanomedicine, we are faced with a growing need for adaptable, scalable technologies that can evolve with these advances.
This presentation will explore how a first-to-market formulation platform challenges conventional limitations by enabling customised approaches tailored to novel materials. We will showcase how the technology was uniquely adapted to achieve what has not previously been done: the first known method to reliably formulate Metal Phenolic Networks. The transition from lab-scale to clinical-scale manufacturing will also be addressed, highlighting the often overlooked disconnect between R&D and translational needs—and how smart design can bridge this gap.